



## DEVELOPMENT AND EVALUATION OF OPHTHALMIC SUSPENSION CONTAINING CORTICOSTEROID AND ANTIBIOTIC

Deepak Kumar Sarangi\*, Debashish Ghose<sup>1</sup>, Suman Kumar Mekap<sup>1</sup>, Rabinarayan Rana<sup>1</sup> and Kanhu Charan Panigrahi<sup>2</sup>

<sup>1</sup>Dept. of Pharmaceutics, Roland Institute of Pharmaceutical Sciences Brahmapur, Odisha, India.

<sup>2</sup>School of Pharmaceutical Education & Research, Berhampur University, Odisha, India.

\*Corresponding Author: Deepak Kumar Sarangi

Dept. of Pharmaceutics, Roland Institute of Pharmaceutical Sciences Brahmapur, Odisha, India.

Article Received on 23/11/2017

Article Revised on 13/12/2017

Article Accepted on 03/01/2018

### ABSTRACTS

In the present study an attempt was made to develop and evaluate the ophthalmic suspension containing corticosteroid drug i.e Prednisolone and Quinolone antibiotic i.e Moxifloxacin. The pH of all formulations was found to be satisfactory in the range of 6.0-6.2, thus there would be no irritation to the patient upon administration of the formulation. The particle size analysis revealed that the particles were in nanometer range and all the formulations showed ideal surface morphology except F2 because after autoclave the particle size of formulation was increased and found to be 17.565  $\mu\text{m}$  which was out of acceptable range. F1 was showed smallest particle size and discrete. The *in vitro* release studies indicated that the formulation F9 showed better effect for desired time and it was found that 120 minutes and 90 minutes for Prednisolone and Moxifloxacin respectively. From the stability studies as per ICH guidelines, it was confirmed that formulations of corticosteroid and antibiotic ophthalmic suspension remained more stable at ambient temperature (25°C) and relative humidity (40%) as compare to other stability conditions.

**KEYWORDS:** Corticosteroids, Antibiotics, ICH, Surface morphology.

### INTRODUCTION

Eye is most interesting organ due to its drug disposition characteristics. Generally, topical application of drugs is the method of choice under most circumstances because of its convenience and safety for ophthalmic chemotherapy. A significant challenge to the formulator is to circumvent (bypass) the protective barriers of the eye without causing permanent tissue damage. Development of newer, more sensitive diagnostic techniques and novel therapeutic agents continue to provide ocular delivery systems with high therapeutic efficacy. Conventional ophthalmic formulations like solution, suspension and ointment have many disadvantages which result into poor bioavailability of drug in the ocular cavity. The specific aim of designing a therapeutic system is to achieve an optimal concentration of a drug at the active site for the appropriate duration.<sup>[1,2]</sup> Ocular disposition and elimination of a therapeutic agent is dependent upon its physicochemical properties as well as the relevant ocular anatomy and physiology. A successful design of a drug delivery system, therefore, requires an integrated knowledge of the drug molecule and the constraints offered by the ocular route of administration.<sup>[3]</sup>

### ROUTES OF OCULAR DRUG DELIVERY

There are several possible routes of drug delivery into the ocular tissues. The selection of the route of administration depends primarily on the target tissue.

## Routes of Ocular drug delivery




Figure 1: Different Routes for Ocular Drug Delivery.

### 1. Topical route

Typically topical ocular drug administration is accomplished by eye drops, but they have only a short contact time on the eye surface. The contact and thereby duration of drug action, can be prolonged by formulation design (e.g. gels, gelifying formulations, ointments and inserts).

### 2. Subconjunctival administration

Traditionally subconjunctival injections have been used to deliver drugs at increased levels to the uvea. Currently this mode of drug delivery has gained new momentum for various reasons. The progress in materials sciences and pharmaceutical formulation have provided new exciting possibilities to develop controlled release formulations to deliver drugs to the posterior segment and to guide the healing process after surgery.<sup>[4,5]</sup>

### 3. Intravitreal administration

Direct drug administration into the vitreous offers distinct advantage of more straightforward access to the vitreous and retina. It should be noted; however that delivery from the vitreous to the choroid is more complicated due to the hindrance by the RPE (Retinal Pigment Epithelium) barrier. Small molecules are able to diffuse rapidly in the vitreous but the mobility of large molecules, particularly positively charged, is restricted.<sup>[6]</sup>

### MECHANISM OF OCULAR DRUG ABSORPTION

Drugs administered by instillation must penetrate the eye and do so primarily through the cornea followed by the non-corneal routes. These non-corneal routes involve drug diffusion across the conjunctiva and sclera and appear to be particularly important for drugs that are poorly absorbed across the cornea.




Figure 2: Ocular Drug Absorption.

### 1. Corneal permeation

The permeation of drugs across the corneal membrane occurs from the precorneal space. Thus, the mixing and the kinetic behavior of drug disposition in tears have a

direct bearing on efficiency of drug absorption into the inner eye. The productive absorption of most ophthalmic drugs results from diffusional process across corneal membrane.<sup>[7,8]</sup>




Figure 3: Corneal Membrane Depicting Various Barriers to drug Absorption.

The efficiency of absorption process is a function of rate and extent at which the transport processes occur. The flux of any drug molecule across the biological membrane depends on the physicochemical properties of the permeating molecule and its interaction with the membrane. The extent to which the transport or absorption process occurs is also function of physiological mechanism of precorneal fluid drainage or turnover.<sup>[9]</sup>

In terms of transcorneal drug permeation, the cornea can be considered to consist of three primary layers (epithelium, stroma and endothelium). The epithelium and endothelium contain on the order of a 100 fold greater amount of lipid material than the stroma. Consequently, depending on the physicochemical properties of a diffusing drug, the resistance offered by the individual layers varies greatly.<sup>[10,11]</sup>

Epithelium, being lipoidal, represents a diffusional barrier offering high resistance to ionic or other aqueous soluble or polar species. In contrast, compounds with relatively low polarity encounter a greater diffusional resistance in the hydrophilic stroma layer. This frequently cited concept of drug permeation across the corneal membrane is referred to as “differential solubility concept”.<sup>[12,13]</sup>

### 2. Non-corneal permeation


Primary mechanism of drug permeation is the sclera is likely to be diffusion across the intercellular aqueous media in the case of structurally similar corneal stroma. Therefore the possibility of partitioning mechanism cannot be eliminated.

Although like cornea, the conjunctiva is composed of an epithelial layer covering an underlying stroma, the

conjunctival epithelium offers substantially less resistance than does the corneal epithelium.<sup>[14,15]</sup>

### DRUGPROFILE

#### API-1 (Prednisolone)



**Drug Category:** Corticosteroids (glucocorticoid), anti-inflammatory action.

**Appearance:** A white or, almost white crystalline powder.

**Solubility:** Freely soluble in chloroform, sparingly soluble in Acetone, Slightly soluble in methanol, practically insoluble in water.

#### Pharmacology

- API-1 is a "soft" steroid belonging to a unique class of glucocorticoids.
- It possesses a metabolically labile 17 beta-chloromethyl ester function which was designed in order to be hydrolyzed to an inactive carboxylic acid moiety.
- This inactive metabolite is more hydrophilic and is thus readily eliminated from the body.
- It is used as a topical agent for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis and iritis.

#### Mechanism of action

- There is no generally accepted explanation for the mechanism of action of ocular corticosteroids.

- However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.
- It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

#### Indication and Uses

As an ophthalmic it is used for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis and selected infective conjunctivides. As a nasal spray, used for the treatment and management of seasonal allergic rhinitis.

**Dosage and Administration:** Shake vigorously before using.

One drop instilled into the affected eye(s) four times daily.


**Side Effects:** Adverse effects include abnormal vision / blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.

**Contraindication:** API-1, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures. It is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

**How to Use:** 0.5% is supplied in a plastic bottle with a controlled drop tip.

**Storage:** Store upright between 15°–25°C (59°–77°F). Do not freeze. Keep out of reach of children.

#### API-2 (Moxifloxacin)



**Drug Category:** Quinolones Antibiotics (Anti-infective).

**Appearance:** A pale yellow or bright yellow, crystalline powder.

**Solubility:** Freely Soluble in glacial acetic acid, Slightly soluble in water; methylene chloride and methanol; practically insoluble in acetone and dichloromethane.

#### Pharmacology

- It is a quinolone/fluoroquinolone antibiotic.
- It is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.
- It is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

#### Mechanism of action

- It acts on DNA gyrase and topoisomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.

**Indication and Uses:** It is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below.

**Table 1: List of gram-positive and gram-negative bacteria.**

#### CONJUNCTIVITIS

| Gram-positive bacteria     | Gram-negative bacteria |
|----------------------------|------------------------|
| Staphylococcus aureus      | Enterobacter cloacae   |
| Staphylococcus epidermidis | Haemophilus influenzae |

**Table 2: List of gram-positive and gram-negative bacteria.**

#### CORNEAL ULCERS

| Gram-positive bacteria     | Gram-negative bacteria |
|----------------------------|------------------------|
| Staphylococcus aureus      | Pseudomonas aeruginosa |
| Staphylococcus epidermidis | Serratia marcescens    |

**Dosage and Administration:** The recommended dosage regimen for the treatments are is:

Instill one to two drops every two to four hours in the affected eye(s) for 1-2 days and Instill one to two drops four times daily from 3 to 7 days.

**Side Effects:** The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periorbital/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness and eye pain. Rare reports of dizziness and nausea have been received.<sup>[16,17]</sup>

**Contraindication:** It is contraindicated in patients with a history of hypersensitivity to quinolones, or to any of the components in this medication.

**How To Use:** 0.3% is supplied sterile in opaque white LDPE plastic bottles and white dropper tips with beige high impact polystyrene (HIPS) caps.

**Storage:** Store at 25°C, excursions permitted to 15-30°C. Protected from light.

## 1. Preformulation studies

### A. Determination of melting point

**Table 3: Reported and observed melting point of API'S.**

| Name  | Reported Wavelength | Observed Wavelength |
|-------|---------------------|---------------------|
| API-1 | 228- 232°C          | 231.60°C            |
| API-2 | 250- 257°C          | 257.38°C            |

### B. Solubility

API-1 was found to be freely soluble in ethyl alcohol, slightly soluble in acetone and practically insoluble in water.<sup>[18,19]</sup>

API-2 was found to be freely soluble in glacial acetic acid and slightly soluble in water, methanol.

### C. IR Spectroscopy

**Table 4: Reported and observed IR frequencies of API-1.**

| Functional Group | Reported Frequencies (in cm-1) | Observed Frequencies (in cm-1) |
|------------------|--------------------------------|--------------------------------|
| -OH              | 3328                           | 3310.50                        |
| -CH              | 2921                           | 2922.21                        |
| -C-O             | 1100                           | 1067.16                        |
| -C=O             | 1655                           | 1607.70                        |
| -CO-O            | 1742                           | 1749.47                        |

**Table 5: Reported and observed IR frequencies of API-2.**

| Functional Group | Reported Frequencies (in cm-1) | Observed Frequencies (in cm-1) |
|------------------|--------------------------------|--------------------------------|
| -NH              | 3124                           | 3052.92                        |
| -C=O             | 1816                           | 1835.60                        |
| -C-F             | 1028                           | 930.67                         |
| -OH              | 620                            | 603.52                         |


**Table 26 and 27** Showed that, functional group frequencies of API-1 and API-2 were in the reported

range which indicates that the obtained samples of API'S was pure.


### D. UV Spectroscopy

**Table 6: Reported and observed wavelength of API'S.**

| Name  | Reported Wavelength | Observed Wavelength |
|-------|---------------------|---------------------|
| API-1 | 245 nm              | 244.60 nm           |
| API-2 | 294 nm              | 294.20 nm           |



**Figure 4: UV spectrum of API-1 in 0.1N HCl.**



**Figure 5: UV spectrum of API-2 in 0.1N HCl.**

**E. Loss on Drying**


After drying 1.0 g of samples of API-1 and API-2 at 60°C for 3 hours in hot air oven. It was found that weight of sample reduced to 0.82 g and 0.92 g. Sample passed the criteria for loss on drying (NMT 0.5% and NMT 0.2%), respectively.

• **Compatibility studies**


Preformulation studies were carried out to study the compatibility of pure drug API-1 and API-2 with

disodium edetate, povidone K-30, citric acid and trisodium citrate prior to the preparation of ophthalmic suspension.<sup>[20,21,22]</sup>

The individual IR spectra of the pure drugs and the combination spectra of the drugs and other excipients are shown in the **Figure 16-22**, which indicate no interaction between API'S and excipients when compared with infrared spectrum of pure drug as all functional group frequencies were present.<sup>[23,24]</sup>



**Figure 6: FT-IR spectrum of API-1.**



**Figure 7: FT-IR spectrum of API-2.**




Figure 8: FT-IR spectrum of API-1 + API-2 combination.




Figure 9: FT-IR spectrum of API-1 + API-2 + Disodium edetate.




Figure 10: FT-IR spectrum of API-1 + API-2 + Povidone K-30.




Figure 11: FT-IR spectrum of API-1 + API-2 + Citric acid.




Figure 12: FT-IR spectrum of API-1 + API-2 + Trisodium citrate.

**2. Standard calibration curve of API-1 and API-2**

Table 29 shows the absorbance of API-1 and API-2 standard solutions containing 2-14 µg/ml of drug in tear fluid (pH 7.4). Figure 23 and 24 shows a representative standard calibration curve with slope, regression

coefficient and intercept respectively. The curve was found to be linear in the range of 2-14 µg/ml at λ<sub>max</sub> 245 nm (API-1) and 245 nm (API-2). The calculation of the drug content and in-vitro release are based on this calibration curve.<sup>[25,26]</sup>

Table 7: Standard calibration curve data of API-1 and API-2.

| Concentration (µg/ml) | Absorbance at 245 nm | Absorbance at 294 nm |
|-----------------------|----------------------|----------------------|
| 2                     | 0.050                | 0.137                |
| 4                     | 0.094                | 0.256                |
| 6                     | 0.147                | 0.384                |
| 8                     | 0.206                | 0.491                |
| 10                    | 0.257                | 0.618                |
| 12                    | 0.301                | 0.727                |
| 14                    | 0.378                | 0.825                |






Figure 13: Calibration curve of API-1.




Figure 14: Calibration curve of API-2.

Table 8: Formulation table with ingredients.

| Name of the Ingredients | F1         | F2         | F3         | F4         | F5         | F6         | F7         | F8         | F9         |
|-------------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Prednisolone            | 0.5%       | 0.5%       | 0.5%       | 0.5%       | 0.5%       | 0.5%       | 0.5%       | 0.5%       | 0.5%       |
| Moxifloxacin            | 0.3%       | 0.3%       | 0.3%       | 0.3%       | 0.3%       | 0.3%       | 0.3%       | 0.3%       | 0.3%       |
| Benzalkonium Chloride   | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      |
| Disodium EDTA           | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      | 0.01%      |
| Citric acid             | 0.08%      | 0.08%      | 0.08%      | 0.08%      | 0.08%      | 0.08%      | 0.08%      | 0.08%      | 0.08%      |
| Trisodium citrate       | 0.18%      | 0.18%      | 0.18%      | 0.18%      | 0.18%      | 0.18%      | 0.18%      | 0.18%      | 0.18%      |
| Glycerin                | 2.5%       | 2.5%       | 2.5%       | 0.5%       | 1.5%       | 2.5%       | 2.5%       | 2.5%       | 2.5%       |
| Tyloxapol               | 0.05%      | 0.05%      | 0.05%      | 0.05%      | 0.05%      | 0.05%      | 0.01%      | 0.03%      | 0.05%      |
| Povidone K-30           | 0.2%       | 0.4%       | 0.6%       | 0.6%       | 0.6%       | 0.6%       | 0.6%       | 0.6%       | 0.6%       |
| Hydrochloric acid       | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  |
| Sodium hydroxide        | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  | adjust pH  |
| Water for Injection     | Up to 10ml | Up to 10ml | Up to 10ml | Up to 10ml | Up to 10ml | Up to 10ml | Up to 10ml | Up to 10ml | Up to 10ml |

3. Evaluation parameters

A. Appearance

The all formulations were found to be off white to pale yellow color redispersible suspension. Terminal sterilization by filtration gives sterile suspension but after sometimes form hard cake at bottom of containers, after shaking cake was dispersed.

B. pH

The pH of all formulations were found to be satisfactory and were in the range of 6.0-6.2. Sterilization by filtration had no effect on formulations.

C. Viscosity

Table 31 shows the viscosity values obtained for formulations TB-3, TB-4 and TB-5 using Brookfield DV-111+ rheometer at different angular velocity. Formulations were shear thinning and an increase in shear stress was observed with increase in angular velocity. The results obtained from the rheological study of prepared suspensions TB-3, TB-4 and TB-5 revealed that the viscosity decreases as the angular velocity increases.

Generally viscosity values in the range of 1-10 cps significantly improve the contact time in the eye. Higher viscosity values offer no significant advantage and have a tendency to leave a noticeable residue on the lid margin. The rheological profile of prepared suspension of corticosteroid and antibiotics is shown in table.

From the above studies, it was concluded that formulation TB-5 was shown best result and it was comparable to the reported value.

#### D. Osmolality

**Table 32** shows the osmolality value for the formulations TB-6, TB-7 and TB-8 were obtained by using advance osmometer, model 3250. The value of each formulation compared with reported value and select best one.

The osmolality range for ophthalmic suspension is 250-310 mOsm/kg.

From the above result it was concluded that the formulation TB-8 was shown best result and it was comparable to reported value.

#### E. Redispersability

After storage at 4°C for 1 week and 40° C for 1 week, each container required 6-8 inversions for complete

removal of sediment adhere to containers and no any aggregates formed were found by visual observation.

From the above result it was concluded that the formulation TB-11 was shown best result and it was comparable to reported value.

#### F. Drop size

The drop size was estimated on average weight basis of drops of ophthalmic solution by using the AUW-220, Shimadzu balance.

All the formulations were found to be satisfactory and were in the range of 25-30 mg.

#### G. Drug Content

**Table 9** shows the percent drug content for formulations. The drug content was found to be in acceptable range for all the formulations except TB-12 and was shown that decreased in the assay values of API'S due to terminal sterilization by autoclaved, it occurred due to degradation of API'S. Percent drug content of formulations were listed in following table.

**Table 9: Result of assay value of API'S.**

| Formulation           | API-1 (%) | API-2 (%) |
|-----------------------|-----------|-----------|
| F1 to F9 (Autoclave)  | 82.1      | 79.1      |
| F1 to F9 (Filtration) | 99.0      | 97.8      |

**H. Preservative Content:** Shows the percent preservative content for formulations. The preservative content was found to be in acceptable range for all the formulations except TB-12. Percent preservative.

#### I. In Vitro Release Studies

The release profile of a drug predicts how a delivery system might function and gives valuable insight into its *in vitro* behaviour. The formulations of corticosteroid and antibiotics suspension TB-14 was subjected to *in vitro* release studies. These *in vitro* release studies were


carried out using simulated tear fluid (STF) of pH 7.4 as the dissolution medium. The drug release data obtained for formulations TB-14 was tabulated in **Table 36 and 37**. **Figure 27** shows the plot of cumulative percent drug released as a function of time for formulation TB-14. It was found that cumulative percent drug release were 97.86% and 99.56% of API-1 and API-2 for formulation TB-14 respectively after 120 minutes and 90 minutes respectively. The *in vitro* release data indicated that the formulation TB-14 showed better effect for desired time.

**Table 10: Result of in-vitro drug release profile of API-1.**

| Time (min) | Absorbance at 245 nm | Conc. (µg/ml) | Drug release (mg/50ml) | % Drug release | % CDR |
|------------|----------------------|---------------|------------------------|----------------|-------|
| 15         | 0.031                | 1.24          | 0.62                   | 12.40          | 12.40 |
| 30         | 0.063                | 2.52          | 1.26                   | 25.20          | 25.44 |
| 45         | 0.096                | 3.84          | 1.92                   | 38.40          | 38.90 |
| 60         | 0.130                | 5.20          | 2.60                   | 52.00          | 52.76 |
| 75         | 0.165                | 6.60          | 3.30                   | 66.00          | 67.04 |
| 90         | 0.202                | 8.08          | 4.04                   | 80.80          | 81.12 |
| 105        | 0.221                | 8.84          | 4.42                   | 88.40          | 90.01 |
| 120        | 0.240                | 9.60          | 4.80                   | 96.00          | 97.86 |

**Table 11: Result of in-vitro drug release profile of API-2.**

| Time (min) | Absorbance at 294 nm | Conc. ( $\mu\text{g/ml}$ ) | Drug release (mg/50ml) | % Drug release | % CDR |
|------------|----------------------|----------------------------|------------------------|----------------|-------|
| 15         | 0.058                | 0.96                       | 0.48                   | 16.11          | 16.11 |
| 30         | 0.117                | 1.95                       | 0.97                   | 32.50          | 32.82 |
| 45         | 0.178                | 2.96                       | 1.48                   | 49.44          | 50.09 |
| 60         | 0.240                | 4.00                       | 2.00                   | 66.66          | 67.64 |
| 75         | 0.297                | 4.95                       | 2.47                   | 82.50          | 83.83 |
| 90         | 0.345                | 5.75                       | 2.87                   | 95.88          | 99.56 |

**Figure 15: In-vitro dissolution comparison of API-1 and API-2.****J. Stability Studies**

Prepared formulations TB-12 of corticosteroid and antibiotic suspension was subjected to pH stability and

containers compatibility studies at  $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$  / NMT 25 % RH,  $60^{\circ}\text{C}$  and  $25^{\circ}\text{C}/40\%$  RH for a period of 1 week, 2week, and 1 month.

**Table 12: Result of pH stability study.**

| Product: Corticosteroid and Antibiotic Ophthalmic Suspension (0.5% + 0.3%) |   |   |              |              |                      |              |              |  |              |              |
|--|---|---|--------------|--------------|----------------------|--------------|--------------|--|--------------|--------------|
| pH stability data of Batch No.= TB-14                                      |   |   |              |              |                      |              |              |  |              |              |
| Description  | Off white to pale yellow colour solution. |   |              |              |                      |              |              |  |              |              |
| Storage condition  | Initial                                   | $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / NMT 25% RH |              |              | $60^{\circ}\text{C}$ |              |              | $25^{\circ}\text{C} \pm 2^{\circ}\text{C}/40\%$ RH |              |              |
| Container type   | 6.00                                      | BFS   | 3-piece HDPE | 3-piece LDPE | BFS                  | 3-piece HDPE | 3-piece LDPE | BFS  | 3-piece HDPE | 3-piece LDPE |
| 1 week   |   | 6.09  | 6.08         | 6.02         | 6.10                 | 6.05         | 5.99         | 6.00   | 6.03         | 5.99         |
| 2 week   |   | 6.02  | 5.97         | 6.01         | 6.21                 | 6.22         | 6.02         | 6.03   | 6.05         | 6.00         |
| 1 month  |   | 6.12  | 6.15         | 6.04         | 6.25                 | 6.24         | 6.05         | 6.05   | 6.09         | 6.01         |

From the above data 3-piece LDPE container was better compatible with formulation as compare to 3-piece HDPE and BFS containers. Also the pH remained within desired range for 3-piece LDPE containers.

Also prepared formulations TB-15 of corticosteroid and antibiotic suspension was subjected to stability studies at  $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$  / NMT 25% RH,  $25^{\circ}\text{C} \pm 2^{\circ}\text{C}/40\% \pm 5\%$  RH,  $30^{\circ}\text{C} \pm 2^{\circ}\text{C}/65\% \pm 5\%$  RH and  $60^{\circ}\text{C}$  for a period of 1 month, 3 month and 6 month as per ICH guidelines. The samples were withdrawn after period of 1 month, 3 month and 6 month and were evaluated for following parameters such as Description, Drug content, Preservative content, pH, Viscosity, Osmolality and Particle size.

The observations are shown in **Table 13**.

**Table 13: Result of stability and containers compatibility studies.**

| Product: Corticosteroid and Antibiotic Ophthalmic Suspension (0.5% + 0.3%) |  |                            |                           |         |         |       |
|--|--|----------------------------|---------------------------|---------|---------|-------|
| Stability data of Batch No.= TB-15   |  |                            |                           |         |         |       |
| Description  | Off white to pale yellow colored redispersible suspension filled in 5 ml 3-piece LDPE (opaque) containers. |                            |                           |         |         |       |
| Stability Condition  | 40°C ± 2°C/ NMT<br>25 % RH   | 25°C ± 2°C/ 40 %<br>±5% RH | 30°C ± 2°C/ 65% ±5%<br>RH | 60°C    |         |       |
| Test parameters  | Initial  | 1 Month                    | 1 Month                   | 1 Month | 1 Month |       |
| Assay (%)  | API-1  | 101.0                      | 103.1                     | 101.2   | 101.8   | 105.2 |
|  | API-2  | 98.8                       | 99.8                      | 98.9    | 99.2    | 100.4 |
| Preservative content (%)   | 110.9  | 112                        | 111.2                     | 111.9   | 112.4   |       |
| pH   | 6.00   | 6.84                       | 6.07                      | 6.24    | 6.98    |       |
| Osmolality (mOsm)  | 299  | 305                        | 300                       | 302     | 316     |       |
| Viscosity (cps)  | 1.92   | 2.84                       | 2.05                      | 2.22    | 2.96    |       |
| Particle size (µm)   | 5.767  | 6.481                      | 5.914                     | 6.212   | 7.324   |       |

From the above data 25°C ± 2°C/ 40% ±5% RH was shown better result than other stability condition as per specification and also shows better compatibility with 3-piece LDPE containers.

The all formulations were found to be off white to pale yellow color redispersible suspension. Terminal sterilization by filtration gives sterile suspension but after sometimes form hard cake at bottom of containers, after shaking cake was dispersed.

### CONCLUSION

In the present study an attempt was made to develop and evaluate the ophthalmic suspension containing corticosteroid and antibiotic.

From the experimental finding, it is concluded that: The melting point, solubility, IR spectrum and UV spectrum of API'S were found as per specification, thus indicating that the API'S were pure. The individual IR spectra of the pure drugs and the combination spectra of the drugs and other excipient indicated that no interaction between API'S and other excipients when compared with infrared spectrum of pure drug as all functional group frequencies were present. The pH of all formulations was found to be satisfactory in the range of 6.0-6.2, thus there would be no irritation to the patient upon administration of the formulation. The particle size analysis revealed that the particles were in nanometer range and all the formulations showed ideal surface morphology except F1 because after autoclave the particle size of formulation was increased and found to be 17.565 µm which was out of acceptable range. F1 was showed smallest particle size and discrete. All the formulations were shear thinning and an increase in shear stress was observed with increase in angular velocity. All the formulations except F6 and F7 showed osmolality within the range i.e. 250-320 mOsm/kg. The redispersability of all optimized formulations were found to be satisfactory, and it was found to be acceptable value as reported i.e. NMT 10 inversions after shaking. The drug content of the prepared formulation was within

the acceptable range and ensures dose uniformity except F9. F9 was shown that decreased in the assay values of API'S due to terminal sterilization by autoclaved, it occurred due to degradation of API'S. The formulation F9 showed maximum drug content i.e. 101% and 98.9% of API-1 and API-2 respectively. The *in vitro* release studies indicated that the formulation F9 showed better effect for desired time and it was found that 120 minutes and 90 minutes for API-1 and API-2 respectively. From the stability studies as per ICH guidelines, it was confirmed that formulations of corticosteroid and antibiotic ophthalmic suspension remained more stable at ambient temperature (25°C) and relative humidity (40%) as compare to other stability conditions.

### REFERENCES

- Hwang S.J. Park H. and Park K., "Ocular drug delivery system", *Pharmazie*, 2003; 58(1): 38-43.
- Vanquez M.Z., Perez-Marcos B., Gomez Amoza J.L. Martinez-Pacheo R., Souto C. and Concheiro A., "Influence of technological variables on release of drugs from hydrophilic matrices", *Drug Dev. Ind. Pharm.*, 1992; 18: 1355-1375.
- Peppas N.A. and Korsmeyer D.W., "Dynamically swollen hydrogels in controlled release application in eyes" in *Hydrogels in medicine and pharmacy*, vol. 3(N.A. Peppas, ed), CRC press, Boca Raton, 1937; 109-137.
- Ford J.L., Rubinstein M.H. and Hogan J.E., "Formulation of sustained release Moxifloxacin eye drop using Povidone", *Int. J. Pharm.*, 1985; 24: 327-338.
- Ford J.L., Rubinstein M.H. and Hogan J.E., "Prednisolone and moxifloxacin eye drop containing hydroxypropyl methyl cellulose" *Int. J. Pharm.*, 1985; 24: 339-350.
- Ford J.L., Rubinstein M.H. and Hogan J.E., "Dissolution of a poorly water soluble drug, indomethacin, from hydroxypropyl methyl cellulose eye ointment", *J. Pharm. Pharmacol*, 1985; 37: 33.
- Xu G. and Sunada H., "Influence of formulation change on drug release kinetics from hydroxypropyl

- methyl cellulose matrix tablets”, *Chem. Pharm. Bull.*, 1995; 43(3): 483-487.
8. Kabanda L., Leferre R.A., Van Bree H.J. and Remon J.P., “In vitro and in vivo evaluation in dogs and pigs of hydrophilic matrix containing propyl thiouracil”, *Pharm. Res.*, 1994; 11: 1663-1668.
  9. Dahl T.C., Calderwood T., Bormeth A., Trimble K. and Piepmer, “Influence of physico-chemical properties of hydroxypropyl methyl cellulose in naproxen release from sustained release matrix tablets”, *J. Contr. Rel.*, 1990; 14: 1-10.
  10. B.M. Singh and K.H. Kim, “Floating drug delivery systems: an approach to controlled drug delivery via gastric retention”, *J. Contr. Rel.*, 2000; 63: 235-259.
  11. J. Timmermans and A.J. Moes, “Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy”, *J. Pharm. Sci.*, 1994; 83: 18-24.
  12. P. Mojaverian, P.H. Vlases, P.E. Kellner and M.L. Rocci, Jr., “Effects of gender, posture, age on gastric residence time of an indigestible solids: pharmaceutical considerations”, *Pharm. Res.*, 1988; 10: 639-644.
  13. Vyas S.P. et al., *Controlled drug delivery concepts and advances*; Vallabh Prakashan, Delhi, First Edition, 2002; 205.
  14. Rubinstein A. and Friend D.R., In: Domb, AJ, ed., *Polymeric site-specific pharmacotherapy*, 1994; 282-283.
  15. Hashim H. and Li A., *Int. J. Pharm.*, 1987; 35: 201-209.
  16. Ritschel W.A., *Exp. Clin. Pharmacol.*, 1991; 13: 313-336.
  17. Shivakumar H.G., Vishakante Gowda D. and Pramod Ku. T.M., “Floating controlled drug delivery systems for prolonged gastric residence: A review” *Ind. J. Pharm. Educ.*, 2004; 38(4): 174.
  18. Hilton A.K. and Deasy P.B., *Int. J. Pharm.*, 1992; 79: 86.
  19. Chickering D.E., Jacob J.S. and Mathiowitz E., “Bioadhesive microspheres II: characterization and evaluation of bioadhesion involving hard, bioerodible polymers and soft tissue”, *Reactive polymers*, 1995; 25: 189-206.
  20. Bechgaard H. and Baggesen S., *J. Pharm. Sci.*, 1980; 69: 1327.
  21. Shivakumar H.G., Vishakante Gowda D. and Pramod Ku. T.M., “Floating controlled drug delivery systems for prolonged gastric residence: A review” *Ind. J. Pharm. Educ.*, 2004; 38(4): 177.
  22. Abrahamsson, B., Alpsten, M., Bake, B., Larsson, A. and Sjogren, J., In-vitro and in-vivo erosion of two different hydrophilic Ocular drug delivery system, *Eur. J. Pharm. Biopharm.*, 1998; 46(1): 69-75.
  23. Altaf, S. and Jones D. B., Development of ophthalmic sustained release formulation of Prednisolone, *Pharm. Res.*, 1998; 15: 119 – 1201.
  24. Atyabi, F. Sharma, HL. Mohammad, HA. Fell, JT., Controlled drug release from coated floating ion exchange resin beads., *J. of Contr. Rel.*, 1996; 42(Oct): 25-28.
  25. Babu, VB. Khar, RK., In vitro and in vivo studies of sustained release floating dosage forms containing salbutamol sulfate., *Pharmazie.* 1990; 45(Apr): 268-270.
  26. Baumgartner, S. Kristl, J. Vrecer, F. Vodopivec, P. Zorko. B., Optimisation of floating matrix tablets and evaluation of their gastric residence time. *Acta Pharmaceutica Sinica.*, 1996; 24(July): 1104-1109.
  27. Baveja, S. K., Ranga – Rao, K. V. and Padmalatha Devi, K., Zero order release hydrophilic eye drops of  $\alpha$ -adrenergic blockers, *Int. J. Pharm.*, 1997; 39: 39-45.
  28. Castellano, I., Goni, I. Ferrero, M. C. and Gurruchaga, M., Synthetic PMMA – Grafted polysaccharide as hydrophilic matrix for controlled release forms, *Drug Dev. Ind. Pharm.*, 1997; 25: 1249 – 1257.
  29. Chen, GL. Hao, WH., In vitro performance of floating sustained release capsules of verapamil., *Drug Dev. and Ind. Pharm.*, 1998; 24(11): 1067-1072.
  30. Chen, SX. Zhu, JB. Hou, HM., Pharmacokinetics and Pharmacodynamics of diltiazem floating tablets. *Chinese Journal of Hospital Pharmacy*, 1996; 16(Feb): 54-56.
  31. Choi, BY. Park, HJ. Hwang, SJ. Park, JB., Preparation of alginate beads for Ocular drug delivery system: effects of CO<sub>2</sub> gas-forming agents., *Int. J. of Pharm.*, 2002; 239(Jun): 81-91.
  32. Desai, S. Bolton, S., Floating controlled – release drug delivery system: in vitro-in vivo evaluation., *Pharm. Res.*, 1993; 10(Sep): 1321-1325.
  33. Diao, Y. Tu, XD., Development and pharmacokinetic study of miocamycin sustained release Ocular drug delivery system, *Acta Pharmaceutica Sinica.*, 1991; 26(Sep): 695-700.
  34. Du, K. Chen, SX. Zhu, JB., Eye drops of zomepirac sodium with cellulose acetate., *J. of Pharm. Sci.*, 1989; 60(Jan): 276-278.
  35. Du, Q. Fan, C. Sun, YL., Preparation and Ocular in vitro evaluation of multiple unit floating granules of aminophylline., *Chinese J. of Hospital Pharm.*, 1996; 16(Feb): 54-56.